Copolymerized PEGlyated Acrylate Hydrogels for Delivery of Dicolofenac Sodium - Pharmaceutical Technology

Latest Issue
PharmTech

Latest Issue
PharmTech Europe

Copolymerized PEGlyated Acrylate Hydrogels for Delivery of Dicolofenac Sodium
Hydrogels are biocompatible drug delivery systems by which the physical properties can be controlled by the cross-linking density. Hydrogels were prepared by copolymerization of acrylic acid monomers in the presence of poly(ethylene glycol)(PEG) to form polyethylene diacrylate (PEDGA). Various molecular weights of PEGs were used for the synthesis of PEGDA to study the effect of molecular weight of PEG on the properties of hydrogels. These hydrogels were further characterized for free water, swelling..


Pharmaceutical Technology


Characterization

Differential scanning calorimetry (DSC) . DSC studies of prepared hydrogels were performed to determine their glass-transition temperatures and confirm the formation of hydrogels. The glass-transition temperature of plain PEGDA was 56.42 °C, whereas the DSC of the polyacrylate cross-linked with PEGDA showed an endothermic peak at 252.58 °C. This temperature was quite higher than the glass-transition temperature of polyacrylic acid (113.6 °C) (31). The change in glass-transition temperature indicates that the individuality of PEGDA and polyacrylate had been lost because of the formation of chemical linkage between PEGDA and the acrylic acid polymer. In addition, the increase in glass-transition temperature of polyacrylate from 113.6 °C to 252.58 °C on cross-linking with PEGDA shows that the thermodynamic stability of the acrylic acid polymer increased because of the formation of cross-linkages.

Morphology. The hydrogels were flexible solids, with somewhat transparent or translucent appearance. On swelling, these became totally transparent. After swelling, their flexibility and rigidity were found to be dependent on the concentration of the cross-linker used. As the concentration of the PEGDA was increased, the flexibility of the hydrogels increased. No significant difference in the morphology of hydrogels, however, was found with the increase in the molecular weight of PEGDA.


Figure 5
Scanning electron microscopy (SEM) was performed to study the internal structure of the hydrogels. SEM photographs (see Figure 5) showed that these hydrogels have a porous polymeric network. Drug molecules can be seen in these photographs in the form of crystals embedded in the hydrogel matrix (see Figure 5b).







Table II: Water uptake and swelling ratio of different acrylic acid hydrogel formulations (n* = 3)
Water-absorbing capacity. Swelling in the presence of aqueous solutions or body fluids is the most important property of a hydrogel. When immersed in aqueous medium, these hydrogels absorb high amounts of water and swell several times their original size. The water-absorbing (hydration) capacity of the hydrogels was studied in terms of percent equilibrium water content and swelling ratio. The hydrogels formed by copolymerization of PEG and acrylate monomers had a very high water-absorbing capacity, absorbing water roughly 2–10 times of their dry weight (see Table II). The homopolymer of acrylic acid can absorb water up to 1.5 times its dry weight.

The equilibrium water content and swelling ratio of the hydrogels formed using the same weight percentage of the PEGDA of higher molecular weight were lower than those found for lower molecular weight PEGDA. Among the hydrogels containing 75% w/w PEGDA, formulation B10 absorbed the maximum amount of water (percent equilibrium water content was 61.16%) and B60 showed minimum water-absorbing capacity (percent equilibrium water content was 55.23%). In the case of the higher molecular weight PEGDA, this result may be attributed to a lower molar percentage of PEGDA, corresponding to the same weight percentage of PEGDA.


ADVERTISEMENT

RELATED CONTENT
Roche Recalls Viracept
Copolymerized PEGlyated Acrylate Hydrogels for Delivery of Dicolofenac Sodium
The Effect of Core and Coating Composition on Drug Release from Directly Compressed Time-Controlled Release Tablets
Near-Infrared Assay and Content Uniformity of Tablets
Maintain Your Moving Parts
blog comments powered by Disqus
LCGC E-mail Newsletters

Subscribe: Click to learn more about the newsletter
| Weekly
| Monthly
|Monthly
| Weekly

Survey
How does your company apply quality-by-design (QbD) principles to manufacturing processes?
To all processes for both new and legacy products
To all process for new products only
To select process for new products only
To select processes for both new and legacy products
Do not use QbD
To all processes for both new and legacy products
18%
To all process for new products only
13%
To select process for new products only
22%
To select processes for both new and legacy products
22%
Do not use QbD
24%
View Results
UPCOMING CONFERENCES

Programs for Investigational and Pre-Launch Drugs
Philadelphia, PA
July 17-18, 2013
Request Brochure

Strategic Pipeline Planning & Portfolio Valuation
Philadelphia, PA
August 13-14, 2013
Request Brochure

MES 2013 - Forum on Manufacturing Execution Systems
Philadelphia, PA
August 14-15, 2013
Request Brochure

Mobile Innovation for the Life Sciences Industry
Philadelphia, PA
August 20-21, 2013
Request Brochure

See All Conferences >>

Eric Langer Outsourcing Outlook Eric LangerOutsourcing's Modest Role as a Cost-Containment Strategy
Patricia Van Arnum Ingredients Insider Patricia Van ArnumIntellectual Property Battles in Solid-State Chemistry
Nathan Jessop Industry Insider Nathan Jessop Campaign Against Counterfeit Drugs Continues
Lynn Torbeck Statistical Solutions Lynn D. TorbeckCompositing Samples and the Risk to Product Quality
 More
Inadequate Access to Medicines Puts EU at Risk
FDA Offers Insight on QbD for Modified-Release Products
Global Biosimilars Market to Reach $2.445 Billion in 2013
Adapting to Change
AstraZeneca and Exco InTouch Collaborate to Augment Current COPD Pathways
FindPharma Custom Search
Source: Pharmaceutical Technology,
Click here